Brief: Viatris Q2 Adjusted EBITDA USD 1,078.8 Million

Viatris

07/08/2025 11:59

Overview

Viatris Q2 2025 revenue beats expectations despite 6% decline yr/yr

Adjusted EPS for Q2 2025 beats analyst expectations, per LSEG data

Company returned over $630 mln to shareholders, including $350 mln in buybacks

Outlook

Viatris expects 2025 total revenues between $13.5 bln and $14.0 bln

Company sees 2025 adjusted EPS between $2.16 and $2.30

Viatris estimates 2025 free cash flow between $1.8 bln and $2.2 bln

Company expects to be in top half of revenue and EPS guidance ranges

Result Drivers

INDORE IMPACT - Negative financial impact from FDA warning letter and import alert on Indore facility affected revenue

BRANDS PERFORMANCE - Strong sales in Greater China and Emerging Markets contributed positively to results

GENERIC SALES - Expected decline due to Indore Impact and competition, offset by growth in specific products and regions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$3.58 bln
$3.47 bln (5 Analysts)
Q2 Adjusted EPS
Beat
$0.62
$0.56 (5 Analysts)
Q2 Net Income
-$4.60 mln
Q2 Adjusted EBITDA
Beat
$1.08 bln
$1.06 bln (2 Analysts)
Q2 Gross Margin
37.2%
Q2 Adjusted Gross Margin
56.6%
Q2 Free Cash Flow
$166.80 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Viatris Inc is $10.50, about 16.7% above its August 6 closing price of $8.75

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release: ID:nPn7N0scQa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)